Drug Class Linked to Worse Outcomes After Transplant Doctors Lounge FRIDAY, Oct. 12 (HealthDay News) -- Kidney transplant patients who receive mammalian target of rapamycin (mTOR) inhibitors after transplant have a greater probability of death or transplant failure than patients receiving calcineurin inhibitors ... |
